Government restricts fixed dose combinations containing 2 chemical compounds for young children

This policy intervention highlights the critical role of the state in safeguarding public health, particularly for vulnerable populations like children. The government's action under Section 26A of the Drugs and Cosmetics Act, 1940 demonstrates the regulatory mechanism available to prohibit or restrict the manufacture, sale, or distribution of drugs deemed risky or lacking therapeutic justification. This aligns with the state's obligation to protect the right to life and health under Article 21 of the Indian Constitution. The decision relies on expert advice from the Drugs Technical Advisory Board, underscoring the importance of evidence-based policymaking in public health. From a UPSC perspective, understanding the statutory framework of drug regulation in India and the tension between public safety and pharmaceutical industry interests is crucial.

The restriction on specific Fixed Dose Combinations (FDCs) brings attention to the rational use of medicines. FDCs, which combine two or more active drugs in a single dosage form, are often marketed for convenience but can pose risks if the combination lacks scientific justification or increases the chance of adverse effects. In this case, the combination of an antihistamine (Chlorpheniramine Maleate) and a decongestant (Phenylephrine Hydrochloride) is deemed unsafe for young children due to potential toxicity and the availability of safer alternatives. This issue touches upon the broader challenge of regulating over-the-counter (OTC) medications and ensuring pediatric safety. Candidates should be familiar with the concept of FDCs, the mandate of bodies like the Central Drugs Standard Control Organisation, and the ongoing efforts to weed out irrational combinations from the Indian market.

The focus on pediatric safety in this regulation underscores a specific facet of child rights – the right to safe healthcare. Children, particularly those under four, have different physiological responses to medications compared to adults, making them more susceptible to adverse drug reactions. The mandatory labeling requirement is a step towards better consumer awareness and empowering parents and caregivers to make informed decisions. This action relates to the broader goal of reducing child morbidity and mortality, a key component of India's commitment to the Sustainable Development Goals (SDGs), specifically Goal 3 (Good Health and Well-being). For the exam, analyzing how regulatory frameworks intersect with child welfare and consumer protection is important.